Published in Cancer Res on March 15, 1999
Real-time PCR in virology. Nucleic Acids Res (2002) 6.71
Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev (2006) 6.03
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol (2011) 2.03
Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A (2005) 1.74
Nasopharyngeal carcinoma. Orphanet J Rare Dis (2006) 1.73
Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn (2001) 1.47
Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol (2001) 1.45
Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA (2008) 1.35
Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol (2003) 1.27
Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J Virol (2012) 1.26
Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut (2002) 1.26
Whole genome amplification of plasma-circulating DNA enables expanded screening for allelic imbalance in plasma. J Mol Diagn (2006) 1.23
Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer (2007) 1.22
Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer (2014) 1.20
Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia (2005) 1.19
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A (2015) 1.18
The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study. Br J Cancer (2014) 1.12
MS analysis of single-nucleotide differences in circulating nucleic acids: Application to noninvasive prenatal diagnosis. Proc Natl Acad Sci U S A (2004) 1.12
Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol (2007) 1.12
Quantitative molecular analysis of virus expression and replication. J Clin Microbiol (2000) 1.11
Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer (2010) 1.10
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A (2015) 1.10
A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer (2011) 1.08
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res (2007) 1.07
Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol (2001) 1.05
Role of the TSG101 gene in Epstein-Barr virus late gene transcription. J Virol (2006) 0.98
Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer (2001) 0.97
Human herpesvirus 8 load in matched serum and plasma samples of patients with AIDS-associated Kaposi's sarcoma. J Clin Microbiol (2003) 0.96
A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol (2011) 0.94
Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population. BMC Cancer (2012) 0.94
Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray. J Infect Dis (2011) 0.93
Integrated mRNA and microRNA transcriptome sequencing characterizes sequence variants and mRNA-microRNA regulatory network in nasopharyngeal carcinoma model systems. FEBS Open Bio (2014) 0.93
Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. Nat Commun (2015) 0.91
Commutability of the Epstein-Barr virus WHO international standard across two quantitative PCR methods. J Clin Microbiol (2014) 0.90
Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis. Curr Infect Dis Rep (2004) 0.90
Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients. Head Neck (2013) 0.90
Unusual MRI findings in an immunocompetent patient with EBV encephalitis: a case report. BMC Med Imaging (2011) 0.88
Comparison of QIAsymphony automated and QIAamp manual DNA extraction systems for measuring Epstein-Barr virus DNA load in whole blood using real-time PCR. J Mol Diagn (2011) 0.87
Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. BMC Cancer (2013) 0.87
Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study. Chin J Cancer (2012) 0.86
Role of chemotherapy in nasopharyngeal carcinoma. Oncol Rev (2012) 0.86
Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A (2015) 0.85
Prognostic implications of dynamic serum lactate dehydrogenase assessments in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Sci Rep (2016) 0.85
Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era. Medicine (Baltimore) (2016) 0.85
Prognostic significance of maximum primary tumor diameter in nasopharyngeal carcinoma. BMC Cancer (2013) 0.85
An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res (2013) 0.85
Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation. J Virol (2013) 0.85
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget (2016) 0.85
Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era. PLoS One (2015) 0.84
Update on molecular diagnostic tests in head and neck cancer. Semin Oncol (2008) 0.84
NF-κB p65 Subunit Is Modulated by Latent Transforming Growth Factor-β Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells. PLoS One (2015) 0.84
Shedding of Epstein-Barr virus and cytomegalovirus from the genital tract of women in a periurban community in Andhra Pradesh, India. J Clin Microbiol (2011) 0.84
Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence. PLoS One (2015) 0.84
Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA. Oncotarget (2016) 0.83
Atypical Epstein-Barr viral genomic structure in lymphoma tissue and lymphoid cell lines. Diagn Mol Pathol (2013) 0.82
Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma. BMC Cancer (2014) 0.82
The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases. Medicine (Baltimore) (2015) 0.82
Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China. Cancer Sci (2015) 0.81
Measurement of Epstein-Barr virus DNA load using a novel quantification standard containing two EBV DNA targets and SYBR Green I dye. Virol J (2010) 0.81
Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys (2011) 0.81
Circulating nucleic acids in plasma and serum: diagnosis and prognosis in cancer. EPMA J (2010) 0.81
Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin Med Oncol (2008) 0.80
Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia. Eur Arch Otorhinolaryngol (2011) 0.80
The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol (2007) 0.80
Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. Oncotarget (2016) 0.79
Levels of VEGF-A mRNA in plasma from patients with colorectal carcinoma as possible surrogate marker of angiogenesis. J Cancer Res Clin Oncol (2008) 0.79
Circulating EBV DNA, Globulin and Nodal Size Predict Distant Metastasis after Intensity-Modulated Radiotherapy in Stage II Nasopharyngeal Carcinoma. J Cancer (2016) 0.78
Quantification of Epstein-Barr virus DNA in patients with idiopathic orbital inflammatory pseudotumor. PLoS One (2013) 0.78
Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. Cancer (2015) 0.78
Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA. Semin Radiat Oncol (2015) 0.77
Biomarkers for use in monitoring responses of nasopharyngeal carcinoma cells to ionizing radiation. Sensors (Basel) (2012) 0.77
Inhibitory activities of microalgal extracts against Epstein-Barr virus DNA release from lymphoblastoid cells. J Zhejiang Univ Sci B (2011) 0.77
Plasma Epstein-Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients: An Observational Study of 89 Cases in an Endemic Area. Medicine (Baltimore) (2015) 0.77
Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. BMC Cancer (2006) 0.76
Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments. BMC Cancer (2006) 0.76
Serum CXCL9 levels are associated with tumor progression and treatment outcome in patients with nasopharyngeal carcinoma. PLoS One (2013) 0.76
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). Invest New Drugs (2015) 0.76
Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference. Clin Biochem Rev (2004) 0.75
Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma. BBA Clin (2014) 0.75
Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma. Oncotarget (2016) 0.75
Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening. PLoS One (2015) 0.75
Correlation between overall survival and differential plasma and tissue tumor marker expression in nasopharyngeal carcinoma patients with different sites of organ metastasis. Oncotarget (2016) 0.75
Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response. Oncoimmunology (2017) 0.75
Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy. PLoS One (2016) 0.75
Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of Cancer. Int J Mol Sci (2017) 0.75
Diagnosis of pediatric nasopharynx carcinoma after recurrent adenoidectomy. Case Rep Otolaryngol (2013) 0.75
Circulating nucleic acids: An analysis of their occurrence in malignancies. Biomed Rep (2016) 0.75
High-density lipoprotein cholesterol as a predictor of poor survival in patients with nasopharyngeal carcinoma. Oncotarget (2016) 0.75
Radiosensitization effect of nedaplatin on nasopharyngeal carcinoma cells in different status of Epstein-Barr virus infection. Biomed Res Int (2014) 0.75
Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma. Oncotarget (2016) 0.75
Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma. Oncol Lett (2015) 0.75
Pre-treatment serum inflammatory cytokines as survival predictors of patients with nasopharyngeal carcinoma receiving chemoradiotherapy. Mol Clin Oncol (2016) 0.75
The incidence of Epstein-Barr virus in nasopharyngeal carcinoma of Jordanian patients. Eur Arch Otorhinolaryngol (2011) 0.75
Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev (2017) 0.75
Prognostic value of serum EBV antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment EBV DNA. Cancer Sci (2017) 0.75
Narrow band imaging endoscopy of the nasopharynx is not more useful than white light endoscopy for suspected nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol (2016) 0.75
Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. Onco Targets Ther (2017) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
The sequence of the human genome. Science (2001) 101.55
Comparative genomics of the eukaryotes. Science (2000) 26.62
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97
The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74
Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 7.53
Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet (1998) 6.88
Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 6.31
A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet (1995) 5.87
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature (1995) 4.93
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology (2001) 4.84
Polymersomes: tough vesicles made from diblock copolymers. Science (1999) 4.76
HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev (2000) 4.67
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med (1998) 4.29
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry (1992) 4.19
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res (1996) 4.11
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature (2000) 4.00
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int (2006) 3.64
Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med (1998) 3.62
Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys (2004) 3.59
A local alignment tool for very long DNA sequences. Comput Appl Biosci (1995) 3.58
Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet (1999) 3.54
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet (2001) 3.48
The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A (1999) 3.43
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
Preparation of tubulin from brain. Methods Enzymol (1982) 3.39
Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet (1999) 3.39
Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev (2000) 3.38
Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell (1995) 3.37
The stabilization of proteins by sucrose. J Biol Chem (1981) 3.34
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity (2000) 3.28
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J (1997) 3.23
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell (1999) 3.15
Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys (2005) 3.14
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol (2002) 3.11
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Applications of network BLAST server. Methods Enzymol (1996) 3.03
Rapid penicillinase paper strip test for detection of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae. Antimicrob Agents Chemother (1977) 3.02
Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer (1999) 2.95
Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun (1980) 2.91
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
The association of cancer and the nephrotic syndrome. Ann Intern Med (1966) 2.88
Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells. Mol Cell Biol (1985) 2.87
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med (1992) 2.78
Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng (2000) 2.73
Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet (1997) 2.69
A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control (2003) 2.67
Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature (1998) 2.65
The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J (1996) 2.64
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther (1996) 2.63
The anatomy and transcription of a telomeric expression site for variant-specific surface antigens in T. brucei. Cell (1987) 2.63
Association of an activator with an RNA polymerase II holoenzyme. Genes Dev (1995) 2.61
The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology (1997) 2.61
Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell (1994) 2.60
Mitochondrial genotype associated with longevity. Lancet (1998) 2.58
Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol (2000) 2.58
Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem (1996) 2.55
Hormonal changes in the grains of rice subjected to water stress during grain filling. Plant Physiol (2001) 2.52
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2000) 2.48